Bio-Rad Laboratories, Inc. (BUWA.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 08:20AM CEST
| Previous Close | 257.40 |
| Open | 256.30 |
| Bid | 257.20 x 5000 |
| Ask | 259.70 x 5000 |
| Day's Range | 256.30 - 256.30 |
| 52 Week Range | 252.00 - 416.60 |
| Volume | |
| Avg. Volume | 8 |
| Market Cap | 7.354B |
| Beta (5Y Monthly) | 0.88 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -20.35 |
| Earnings Date | May 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 856.25 |
Business WireBio-Rad Announces Life Science Group Management Changes
HERCULES, Calif., April 26, 2024--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024. He succeeds Dr. Simon May, who has announced his decision to leave the company to pursue another professional opportunity.
ZacksNew Strong Sell Stocks for April 19th
ATNI, ABR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on April 19, 2023.
ZacksBio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
The ongoing weakness in the biopharma end markets and tightening of sanctions against Russia is likely to have hurt Bio-Rad's (BIO) first-quarter 2024 growth.
© 2024 Yahoo. All rights reserved.